| Literature DB >> 30782858 |
Patricia Louis1, Brian Mercer2, Aiko M Cirone1, Christina Johnston1, Zachary J Lee1, Nwadiuto Esiobu2, Zhongwei Li1, Jianning Wei1, C Kathleen Dorey3, Yoshimi Shibata4, Changlong Nan1.
Abstract
Chitin is a natural N-acetylglucosamine polymer and a major structural component of fungal cell walls. Dietary chitin is mucoadhesive; anti-inflammatory effects of chitin microparticles (CMPs; 1- to 10-μm diameters) have been demonstrated in models of inflammatory bowel disease (IBD). The goals of this study were to assess (i) whether CMPs among various chitin preparations are the most effective against colitis in male and female mice and (ii) whether host chitin-binding Toll-like receptor 2 (TLR2) and CD14 are required for the anti-inflammatory effect of chitin. We found that colitis in male mice was ameliorated by CMPs and large chitin beads (LCBs; 40 to 70 μm) but not by chitosan (deacetylated chitin) microparticles, oligosaccharide chitin, or glucosamine. In fact, LCBs were more effective than CMPs. In female colitis, on the other hand, CMPs and LCBs were equally and highly effective. Neither sex of TLR2-deficient mice showed anti-inflammatory effects when treated with LCBs. No anti-inflammatory effect of LCBs was seen in either CD14-deficient males or females. Furthermore, an in vitro study indicated that when LCBs and CMPs were digested with stomach acidic mammalian chitinase (AMC), their size-dependent macrophage activations were modified, at least in part, suggesting reduced particle sizes of dietary chitin in the stomach. Interestingly, stomach AMC activity was greater in males than females. Our results indicated that dietary LCBs were the most effective preparation for treating colitis in both sexes; these anti-inflammatory effects of LCBs were dependent on host TLR2 and CD14.Entities:
Keywords: Candida albicanszzm321990; acidic mammalian chitinase; chitin binding protein; dysbiosis; inflammatory bowel disease; large chitin beads
Mesh:
Substances:
Year: 2019 PMID: 30782858 PMCID: PMC6479031 DOI: 10.1128/IAI.00006-19
Source DB: PubMed Journal: Infect Immun ISSN: 0019-9567 Impact factor: 3.441